Yes, targeting telomerase is a promising approach in cancer therapy. Inhibiting telomerase can lead to progressive telomere shortening in cancer cells, eventually triggering cell death. Several strategies are under investigation, including small-molecule inhibitors, antisense oligonucleotides, and immunotherapy. One notable example is the drug imetelstat, which has shown potential in clinical trials for treating certain types of cancers.
